Everolimus denied as experimental or investigational by Kaiser Permanente?

Kaiser Permanente's specific coverage criteria for everolimus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Kaiser Labels Everolimus Experimental — and How to Challenge It

Everolimus has FDA approval for multiple indications, including certain breast cancers, renal cell carcinoma, neuroendocrine tumors, tuberous sclerosis complex, and transplant rejection prophylaxis. An "experimental" or "investigational" denial from Kaiser most commonly occurs in one of two scenarios: (1) the requested use falls outside the FDA-approved indications listed in Kaiser's own coverage policy, or (2) Kaiser's policy has not yet been updated to reflect a recently approved indication. In either case, this denial type is directly appealable and is frequently overturned when the request falls within an FDA-approved use or a use supported by a recognized compendia listing.

## The Federal Appeal Framework

Under ACA §2719, experimental-use denials are among the most strongly protected appeal categories. You have the right to internal appeal followed by independent external review. The external review window is typically four months after final internal denial. Request expedited review for urgent oncology cases — timelines can be compressed to 72 hours.

For self-funded ERISA plans, you are entitled under ERISA §503 to a full-and-fair review with written disclosure of the specific clinical criteria or guidelines Kaiser relied upon to characterize the use as experimental.

Federal law (the ACA and ERISA) also requires that plans cover cancer treatments consistent with recognized clinical compendia such as the NCCN Drugs and Biologics Compendium. If the requested use appears in a recognized compendium, cite that explicitly.

## Documentation to Gather

• FDA approval documentation: Print the FDA drug label (from DailyMed or FDA.gov) showing the exact approved indication that matches this patient's diagnosis.
• Compendia listing: A printout of the relevant NCCN compendium entry or other recognized oncology/specialty compendium listing supporting this use.
• Pathology and staging records: Confirmed diagnosis, histology, and staging documents that align with the approved or compendium-listed indication.
• Treating physician's medical-necessity letter: A letter from the specialist explicitly stating the indication, referencing FDA approval or compendia support, and explaining why this is not investigational.
• Any published clinical guideline reference: Generic reference to the applicable specialty society guideline (e.g., the applicable NCCN guideline) recommending this agent for this indication.

## Criteria-Mapping Structure

| Kaiser "Experimental" Policy Criterion | Rebuttal Evidence | |---|---| | [Copy the experimental-use definition from Kaiser's clinical policy] | [FDA label section / compendium entry / chart diagnosis that meets the approved use] |

## Practical Next Steps

1. Obtain Kaiser's denial letter citing the exact policy language used to classify this use as experimental. 2. Confirm whether the patient's diagnosis matches an FDA-approved indication on the current label. 3. Check whether the use appears in a recognized compendium (NCCN, etc.). 4. Have the treating physician draft a letter directly rebutting the experimental characterization. 5. File internally with supporting documentation attached. 6. If denied, escalate immediately to external review — IRO reviewers apply FDA labeling and recognized compendia, not just the plan's internal policy definitions.